Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ursula Urner"'
Autor:
Corinne D C Eggenschwiler, Ursula Urner-Bloch, Florentia Dimitriou, Joanna Mangana, Martin Urner, Nicholas Mitsakakis, Reinhard Dummer
Publikováno v:
European Journal of Cancer. 144:215-223
Background Treatment with immune checkpoint and BRAF/MEK inhibitors has significantly improved the survival of patients with advanced cutaneous melanoma and other metastatic malignancies. Therapy-related uveitis is a rare ocular adverse event, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a555a58140e55c34de514e94a4446c28
https://doi.org/10.1016/j.ejca.2020.11.027
https://doi.org/10.1016/j.ejca.2020.11.027
Autor:
Alexandra Valeska Matter, Simone M. Goldinger, Sara Micaletto, Ursula Urner-Bloch, Reinhard Dummer
Publikováno v:
The Oncologist
Melanoma can be classified based on the detection of relevant oncogenic driver mutations. These mutations partially determine a patient's treatment options. MEK inhibitors have demonstrated little efficacy in patients with NRAS‐mutated melanoma owi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::145601bc949f4b0f83188d4b388aa2ac
https://doi.org/10.1634/theoncologist.2019-0656
https://doi.org/10.1634/theoncologist.2019-0656
Autor:
I Blume, Simone M. Goldinger, Sara Micaletto, A Valeska Matter, Reinhard Dummer, J. Mangana, Ursula Urner-Bloch, J Narainsing
Publikováno v:
The British journal of dermatologyReferences. 182(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b8e43b892d5160c5ca0eb8afed48e3
https://pubmed.ncbi.nlm.nih.gov/31436845
https://pubmed.ncbi.nlm.nih.gov/31436845
Autor:
Samia Abed Maillard, Lukas Flatz, Daniel E. Speiser, Reinhard Rüesch, Fabienne Keller, Stefan Diem, Simone M. Goldinger, Ursula Urner-Bloch, Reinhard Dummer, Marco Siano
Publikováno v:
Journal of Immunotherapy
Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1463f1e7d3676f85f258311a918183d6
https://pubmed.ncbi.nlm.nih.gov/27662340
https://pubmed.ncbi.nlm.nih.gov/27662340
Autor:
Ursula Urner-Bloch, Martin Urner, Nicoletta F Jaberg-Bentele, Anna L. Frauchiger, Simone M. Goldinger, Reinhard Dummer
Publikováno v:
European journal of cancer (Oxford, England : 1990). 65
Background Mitogen-activated protein kinase kinase (MEK) inhibitors have aroused considerable interest in oncology. Activity has been demonstrated in various types of cancer, especially melanoma. MEK inhibitors induce a transient retinopathy, conside
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3feb9dc5459aeebe0629ebcba52b4513
https://pubmed.ncbi.nlm.nih.gov/27497344
https://pubmed.ncbi.nlm.nih.gov/27497344
Autor:
Anna Wirz-Justice, Ursula Urner, Charlotte E. Remé, Ursula Heinen, Alexandra Prünte, Peter Graw
Publikováno v:
Biological Psychiatry. 41:743-746
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e322ebab1e425943c0964f5ce982ea91
https://doi.org/10.1016/s0006-3223(97)00001-2
https://doi.org/10.1016/s0006-3223(97)00001-2